Review Article
An Update on the Changing Indications for Androgen Deprivation Therapy for Prostate Cancer
Table 1
Summary of androgen deprivation indications.
| ADT likely unwarranted | ADT still warranted |
| Localized disease | Advanced disease | (i) Preprostatectomy/postprostatectomy [30] | (i) PSA > 50, PSADT < 12 months [38] | (ii) Prior to EBXRT/Brachytherapy [33–36] | (ii) Prior to EBXRT [43–47] | (iii) No primary treatment [37] | (iii) Local obstructive symptoms and or metastatic disease [50] | (iv) Biochemical recurrence after therapy with PSADT > 12 months [53] | (iv) Lymph node involvement at prostatectomy [49] | | (v) Biochemical recurrence after therapy with high risk of death from prostate cancer [55–57], |
|
|
Abbreviations. ADT: androgen deprivation therapy; EBXRT: external beam radiation; PSA: prostate-specific antigen; PSADT: prostate-specific antigen doubling time.
|